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OBJECTIVES: To establish cut-off values for growth hormone concentrations using clonidine as a secretagogue
and an immunochemiluminescent assay as the method of measurement and to analyze the response time as
well as the influence of gender, nutritional status and pubertal stage.
METHODS: A total of 225 tests were performed in 3 patient groups, categorized as group 1 (normal), group 2
(idiopathic short stature) and group 3 (growth hormone deficiency). Among the 199 disease-free individuals,
138 were prepubertal, and 61 were pubertal. Clonidine (0.1 mg/m2) was orally administered, and the growth
hormone level was measured by immunochemiluminescent assay. The growth hormone peak and the difference
between the growth hormone peak and the baseline level were then analyzed. Statistical analyses were
performed using Student’s t-test or the Mann-Whitney test and Kruskal-Wallis test followed by Dunn’s post hoc
test. Cut-off values were determined using a receiver operating characteristic curve.
RESULTS: Group 1 and group 2 had no difference in growth hormone peak, gender, body mass index standard
deviation score, or pubertal stage. Group 3 exhibited a significantly lower growth hormone peak than the other
groups did. The receiver operating characteristic curve demonstrated that growth hormone concentrationsX 3.0
ng/mL defined responsiveness to clonidine. In total, 3.02% of individuals in group 1 and group 2 were considered
false positive, i.e., these children lacked growth hormone deficiency and had a peak below 3.0 ng/mL.
CONCLUSION: Clonidine-stimulated growth hormone concentrations X3 ng/mL, as measured by immuno-
chemiluminescent assay, suggest responsiveness to the stimulus regardless of gender, body mass index standard
deviation score or pubertal stage.
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’ INTRODUCTION
After birth, growth in height results from endogenous factors,
such as hormones and genetic background, and from exogen-
ous factors, such as proper nutrition and the psychosocial and
emotional conditions under which the individual develops (1,2).
Growth rate and weight gain are the main parameters
used by pediatricians to monitor the height development
and health of a child. When short stature or a growth rate
decrease is detected, the child should be evaluated according
to an investigative protocol for short stature to define the
etiology and appropriate therapy (3).
In specific protocols, children with certain conditions
diagnosed during the evaluation of short stature, such as
growth hormone (GH) deficiency (GHD) as well as Turner
syndrome (TS) in girls in particular, can receive recombinant
human GH (rhGH) therapy from the Brazilian Ministry of
Health (Ministério da Saúde do Brasil). However, for this, it is
first necessary to perform a differential diagnosis between
these conditions and familial, constitutional and/or idiopathicDOI: 10.6061/clinics/2016(04)09
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short stature (ISS) in addition to other diseases that manifest
with short stature (4).
GHD can be detected directly, by measurements of GH
and its effector, insulin-like growth factor-1 (IGF-1), or
indirectly, by evaluation of the growth rate over a year.
Under normal conditions, basal GH concentrations are low
and often undetectable. The evaluation of GH secretion can
be performed by determining either the integrated GH
secretion over 12 to 24 hours, which is an unfeasible
methodology from a clinical point of view, or the GH
concentration after pharmacological stimulation, with a lack
of response to at least two different secretagogues indicating
a problem (5). The most frequently used pharmacological
stimuli in Brazil are clonidine, an a-agonist drug that pro-
motes the release of GH-releasing hormone (GHRH) (6), and
insulin-induced hypoglycemia (7), in addition to glucagon,
arginine, L-dopa and exercise, among others (5).
It has been arbitrarily agreed that the plasma-stimulated
GH level (the GH peak) that is indicative of adequate
secretion is X10 ng/mL, as assayed by radioimmunoassay
(RIA) (6-11). Below this cut-off, individuals are considered as
GH deficient within the appropriate clinical context (2,3).
Beginning in the 1990s, more sensitive and specific immuno-
metric methods were developed in addition to international
benchmarks for measuring GH and other hormones, such as
luteinizing hormone (LH), thyroid-stimulating hormone (TSH),
and IGF-1. New reference standards for measurements of the
baseline and cut-offs in stimulation tests were then imposed,
suggesting the need to adapt treatment protocols (12-15).
Since 1996, concentrations of GH have been determined at
the Federal University of Triangulo Mineiro (Universidade
Federal do Triângulo Mineiro - UFTM) by immunochemilu-
minescent assay (ICMA), and clonidine and insulin are the
most commonly used GH secretagogues. In the present
study, to reassess the reference standards and to determine
the cut-off value for the GH peak, 225 clonidine stimulation
tests performed between 2000 and 2014 were evaluated.
Other features, such as the time to the greatest response,
gender differences and the influence of prepubertal and
pubertal developmental stages, were also studied.
’ SUBJECTS AND METHODS
This prospective study was approved by the UFTM Ethics
Committee. Patients were selected in the Pediatric Endocri-
nology Unit, where they were evaluated for short stature
according to the standardized protocol for conduct in the
clinic. All patients completed an initial form covering their
history, and a physical examination was performed. The
following anthropometric data were also calculated: height
standard deviation score (SDS), growth velocity SDS, weight
SDS, body mass index (BMI) and BMI SDS (16). Additionally,
the pubertal stage was determined (17,18), and the pertinent
data were plotted on growth charts for Brazilian children (19).
After general biochemical tests, TSH testing, x-rays of the skull
and bone age determination according to Greulich and Pyle (20)
were performed, quarterly monitoring of the patients was
initiated. The first stimulation test was requested after monitor-
ing the growth rate for a time ranging from 6 to 12 months,
unless panhypopituitarism or central nervous system (CNS)
tumors had been immediately identified. The conditions that
resulted in the test being indicated for a specific child were
short stature, a height SDS o-2, a decreased growth velocity
according to age and a tendency toward a shift in the growth
path observed in the growth chart (3,5).
When the test was indicated, by the morning (7:00 am), the
child was greeted in the functional testing room by a
physician and a nurse trained to conduct the exam. The child
was then placed in the supine position, and a vein was
punctured for infusion of 0.9% saline. After 40 minutes of rest,
the first 5 mL sample of whole blood was collected. The GH
concentration in this sample was considered as the baseline
and was used for comparison with the stimulated concentra-
tions. After obtaining the baseline sample, 0.10 mg/m2
clonidine was administered orally, and then blood samples
were collected after 30, 60, 90 and 120 minutes. The whole
blood was centrifuged at 4000 rpm, and the serum was then
separated and kept at -20oC until the hormone assay.
GH concentrations were determined by ICMA using an
automated system (IMMULITE 1000 Immunoassay System,
Siemens, Berlin, Germany) and commercial kits obtained from
DPC (Diagnostic Products Corporation, Los Angeles, CA,
USA). This sandwich assay uses two antibodies specific for the
circulating 22 kDa form of GH and the standard calibrator
80/505 from the World Health Organization, with a detection
limit of 0.02 mg/L (1 m/L = 1 ng/mL) and an intra-assay
coefficient of 5.7% for GH concentrations of 0.02 to 5 mg/L (21).
In a previous pilot study using the same method, as
subsequently confirmed by other authors (5,22), increases in
clonidine-stimulated GH concentrations X5 ng/mL were
considered as a normal response, and all of the diagnostic and
clinical decisions considered this figure as a cut-off value.
For cases where there was a lack of response to the clonidine
test, the second test was the insulin tolerance test (ITT), used
according to conventional descriptions (7,11), and a GH con-
centration X5 ng/mL was assumed to indicate a normal
response. None of these tests was preceded by testosterone or
estradiol administration to sensitize the test (priming). The GH
peak (the greatest increase achieved) and DGH (the difference
between the greatest increase and the baseline) were considered
for all of the samples obtained during each of the tests.
In addition to the GH stimulation tests, girls with short
stature had their karyotypes determined according to the
GTG-banding technique, with an analysis of 100 metaphases
(23). IGF-1 concentrations were not determined in the
laboratory of the UFTM, but rather were outsourced to other
laboratories and thus were determined according to variable
technical and reference standards, which made correlation
with the GH response to secretagogues unfeasible (15).
For evaluation of the clonidine test, the selected cases were
divided into 3 groups:
 Group 1 (G1) consisted of 56 children without disease and
with small delays in weight and a height SDS 4-2. They
were later considered as the control group because the
longitudinal follow-up demonstrated that these children
did not have disease and that in most cases, their heights
normalized. This group was categorized based on the
height SDS calculated during the consultation during which
the GH stimulation test with clonidine was indicated. The
indication for the test was justified by a reduction in the
growth rate or by a temporary shift in growth.
 Group 2 (G2) consisted of 143 patients with ISS and a
height SDS o-2. Children who were small for gestational
age (SGA) or who had chronic clinical conditions were not
included.
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 Group 3 (G3) consisted of 26 children with GHD. Seven
cases were due to panhypopituitarism, 13 children had
isolated deficiency characterized by decreased growth
velocity (o2 cm/year) that improved with rhGH therapy,
and 6 children had craniopharyngioma (3,5).
Statistical analysis
The data distribution was analyzed using the Kolmogorov-
Smirnov test, and the homogeneity of variances was verified
by Levene’s test. As our data showed a nonparametric
distribution, for comparisons of two independent samples
(including comparisons between males and females and
between the prepubertal and the pubertal stages within each
clinical group), the Mann-Whitney test was used, and for
comparisons of three independent groups, the Kruskal-Wallis
test followed by Dunn’s post hoc test was used. Correlations
between the GH peak and the BMI SDS were obtained using
the Spearman test.
Finally, a receiver operating characteristic (ROC) curve
was constructed by calculating the sensitivity and specificity
for all possible cut-off values of the GH peak. The area under
the ROC curve represents the probability that the test will
distinguish affected individuals from unaffected individuals.
For the best cut-off value in each comparison group, the
sensitivity with a 95% confidence interval (CI), the specificity
(95% CI) and positive and negative predictive values (95% CI)
were obtained.
Comparisons and data from the ROC curve analysis were
obtained using SPSS version 20 and MedCalc 10.3 software,
respectively. The observed differences were considered
significant when the significance level (p) was less than 0.05.
’ RESULTS
A total of 225 GH stimulation tests were analyzed, with 199
of them performed in children categorized as normal based
on the height SDS (G1; n=56) or as having ISS (G2; n=143).
Additionally, 26 tests were performed in children with
GHD (G3).
G1 (height SDS ranging from normal to X-2) consisted of
56 children, including 33 boys and 23 girls. These children
were aged 10.4 years.months (yr.mo) (median) (minimum: 3.6
and maximum: 14.0), with a height SDS of -1.53 (-1.94 to 1.96)
and a BMI SDS of -0.59 (-1.80 to 1.10). The median baseline
GH concentration was 0.27 ng/mL (0.05 to 3.00). The
maximum value in response to the test (GH peak) was 8.00
ng/mL (2.00 to 23.00). These data as well as bone age and
DGH values are shown in table 1.
In this group, 6 (10. 71%) patients were considered
nonresponsive to the clonidine test according to the reference
standards at the time (X5 ng/mL); these patients underwent
the ITT, in which they exhibited normal responses (GH peak
X5 ng/mL), suggesting that they had been false positive for
GHD when subjected to the clonidine test.
G2 (height SDS o-2) consisted of 143 children, including
83 boys and 60 girls, aged 9.0 yr.mo (median) (minimum: 3.0
and maximum: 14.7). These children had a height SDS of
-2.70 (-5.24 to -2.30) and a BMI SDS of -0.80 (-1.60 to 2.0). The
median baseline GH concentration was 0.37 ng/mL (0.01 to
2.30), and the GH peak response was 9.00 ng/mL (1.00 to
36.00). These data as well as bone age and DGH values are
shown in Table 1. In this group, 21 (14.68%) patients were
considered nonresponsive to the clonidine test, underwent
the ITT and yielded a normal response.
In G3, 26 children had a proven diagnosis and outcome of
GHD. The age of these children was 9.3 yr.mo (minimum:
3.11 and maximum: 15.4), and they had a height SDS of -3.60
(-9.44 to -2.16) and a BMI SDS of -0.18 (-4.50 to 3.00). The
median baseline GH concentration was 0.33 ng/mL (0.05 to
2.29), and the GH peak response was 1.00 ng/mL (0.00 to
2.20). These data as well as bone age and DGH values are
shown in Table 1. All patients in this group underwent the
ITT and were nonresponsive in this test as well as the
previous test. In the ITT, the baseline GH concentration was
0.33 ng/mL (0.10 to 0.59), and the GH peak was 0.40 ng/mL
(0.05 to 1.00).
Intra- and inter-group comparisons
Comparisons between the three groups are depicted in
table 1. As expected, when all of the groups were compared,
the height SDS showed a significant difference (G2,G3oG1;
G3oG1,G2) between the groups, and the bone age in G2 was
lower than that in G1. There was no significant difference in
Table 1 - Anthropometric data from and baseline and clonidine-stimulated (0.10 mg/m2 BS) GH concentrations in normal subjects (G1),
in patients with ISS (G2), and in patients with GHD (G3), with the ITT performed in nonresponsive clonidine patients.
DATA G1 (n: 56) G2 (n: 143) G3 (n: 26) Between groups1 Comparisons p-value
Age2 (yr.mo) 10.4 (3.6-14.0)9 9.0 (3.0-14.7) 9.3 (3.11-15.4) 0.344
Bone Age (yr.mo) 9.0 (2.0-13.0) 7.0 (1.0-14.0) 5.0 (2.0-13.0) 0.031(G14G2)
Height SDS3 -1.53 (-1.94-1.96) -2.70 (-5.24--2.30) -3.60 (-9.44--2.16) 0.0001(G2oG1; G3oG1; G3oG2)
GV SDS4 -2.00 (-6.00-0.00) -2.00 (-8.00-0.00) -4.00 (-7.00--1.00) 0.0003(G3oG2; G3oG1)
BMI5 SDS -0.59 (-1.80-1.10) -0.80 (-1.60--2.00) -0.18 (-4.50-3.00) 0.131
Baseline GH (ng/mL) 0.27 (0.05-3.00) 0.37 (0.01-2.30) 0.33 (0.05-2.29) 0.187
GH Peak6 (ng/mL) 8.00 (2.00-23.00) 9.00 (1.00-36.30) 1.00 (0.00-2.20) o 0.0001(G3oG1; G3oG2)
DGH7 7.60 (0.30-22.65) 8.87 (0.00-33.00) 0.00 (0.00-2.00) o 0.0001(G3oG1; G3oG2)
ITT8 GH Peak (ng/mL) 12.00 (5.50-21.00) 11.70 (6.00-23.30) 0.40 (0.05-1.00) -
1: Kruskal-Wallis test followed by Dunn’s test;
2: Chronological age represented in years (yr.) and months (mo.);
3: SDS = standard deviation score;
4: GV SDS = growth velocity SDS;
5: BMI = body mass index;
6: GH Peak = maximum clonidine-stimulated GH concentration;
7: DGH = GH peak – baseline GH;
8: G1 (10.71%; n=6) and G2 (14.68%; n=21);
9: Values expressed as the median (minimum and maximum = minimum - maximum).
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the baseline GH, but the GH peak concentrations (as well as
DGH) in G3 were lower than those in G1 and G2. No
differences were found between G1 and G2 (Table 1).
To study the influence of gender and puberty on the GH
response to clonidine, the patients from G1 and G2 were
divided into male, female, prepubertal and pubertal sub-
groups; in this last subgroup, the patients were in Tanner
stages 2 and 3. Except for differences in chronological age
and certain expected significant differences in anthropo-
metric data, there were no significant differences in the
baseline or stimulated GH level in G1 (Table 2) and G2
(Table 3) according to gender or pubertal development.
In these groups, there was also no correlation between the
GH peak (as well as DGH) and the BMI SDS, independent of
gender or puberty (p40.005). The greatest GH increases
occurred after 60 minutes in 63.31% of the subjects, after
90 minutes in 25.62% and after 120 minutes in 6.03%.
Construction of the ROC curve initially aimed to establish
whether one group could be differentiated from another
based on the GH peak and DGH parameters. G1 compared
with G2 proved to be unable to define a possible growth
deficit according to the GH evaluation. Combined G1+G2
and G2 were then tested against G3, and both comparisons
were significant (po0.001), i.e., both the groups of children
with ISS (G2) and the normal children could be differentiated
from the children with GHD by the ROC curve. The best
parameter for differentiating the groups was the GH peak,
and a 3.0 ng/mL value was the cut-off. In this case, the GH
peak demonstrated a sensitivity of 100.00% (86.80% to
100.00%) and a specificity of 96.98% (93.60% to 98.90%) in
identifying children with GHD (Figure 1).
’ DISCUSSION
Studies conducted in past decades have presented data
supporting the therapeutic use of rhGH in children with
isolated GHD or GHD in association with another deficiency
(panhypopituitarism) as well as in children with ISS or
who are SGA; in children with chronic renal failure; and
in children with genetic syndromes such as TS, Noonan
syndrome and Prader-Willi syndrome (24). Although rhGH
therapy is temporary for most of these conditions, it must be
permanent in cases of GHD; therefore, a differential diagnosis
should be performed with the other conditions, particularly
in children with ISS or who are SGA (3,5,24).
Children with GHD are identified when they do not
respond to two GH stimulation tests, and despite all of the
controversies involving the need for these GH tests (25,26),
Table 2 - Anthropometric data from and baseline and clonidine-stimulated GH concentrations in normal patients (G1), distributed and
compared according to gender and pubertal development.













Age2 (yr.mo) 10.90 (4.90-13.70)7 12.80 (10.60-14.00) o 0.0001 8.50 (3.60-11.10) 11.20 (9.11-13.00) o 0.0001 o 0.0001 0.014
Bone Age (yr.mo) 9.00 (3.00-13.00) 12.50 (8.00-13.00) o 0.0001 8.00 (2.00-12.00) 9.00 (7.00-13.00) o 0.0001 0.562 0.227
Height SDS3 -1.15 (-1.94-1.96) -1.60 (-1.91--1.24) 0.946 -1.88 (-1.93-108) -1.57 (-1.92-0.09) 0.003 0.014 0.706
BMI4 SDS -0.61 (-1.40-1.00) -1.85 (-1.80--0.20) 0.027 -0.52 (-1.70-1.10) -0.15 (-1.10-0.90) 0.194 0.377 0.004
Baseline GH (ng/mL) 0.30 (0.05-1.90) 0.10 (0.05-2.10) 0.497 0.20 (0.05-3.00) 0.71 (0.05-2.00) 0.190 0.439 0.234
GH Peak5 (ng/mL) 9.00 (3.00-23.00) 9.00 (3.00-22.00) 0.653 8.00 (2.00-17.00) 8.00 (3.00-14.00) 0.311 0.472 0.442
DGH6 (ng/mL) 8.92 (1.15-22.65) 8.78 (3.27-22.00) 0.572 7.16 (0.30-14.80) 7.21 (2.87-13.42) 0.156 0.305 0.435
1: Mann-Whitney test;
2: Chronological age represented in years (yr.) and months (mo.); 3: SDS = standard deviation score;
4: BMI = body mass index;
5: GH Peak = maximum clonidine-stimulated GH concentration;
6: DGH = GH peak – baseline GH.
7: Values expressed as median (minimum and maximum = minimum-maximum).
Table 3 - Anthropometric data from and baseline and clonidine-stimulated GH concentrations in patients with ISS (G2), distributed and
compared according to gender and pubertal development.













Age2 (yr.mo) 8.20 (3.00-14.70)7 13.70 (10.00-14.60) o 0.0001 6.60 (3.40-13.90) 11.50 (9.01-13.50) o 0.0001 0.035 o 0.0001
Bone Age (yr.mo) 4.20 (1.00-14.00) 11.00 (6.70-14.00) o 0.0001 4.20 (1.00-11.00) 10.00 (6.00-13.00) o 0.0001 0.240 0.117
Height SDS3 -2.81 (-5.24--2.30) -2.78 (-5.05--2.30) 0.704 -2.67 (-5.20--2.25) -2.35 (-3.54--2.10) 0.045 0.692 0.189
BMI4 SDS -0.83 (-1.60-1.70) -1.42 (-1.30--0.60) 0.020 -0.52 (-1.20-1.70) -0.64 (-1.20-0.80) 0.106 0.031 0.135
Baseline GH (ng/mL) 0.44 (0.01-2.30) 0.40 (0.05-1.80) 0.591 0.47 (0.01-2.29) 0.34 (0.08-1.87) 0.788 0.636 0.654
GH Peak5 (ng/mL) 8.78(0.65-33.30) 8.70 (3.30-25.00) 0.518 8.40 (0.00-36.30) 9.45 (3.50-19.80) 0.614 0.887 0.934
DGH6 (ng/mL) 8.00 (0.00-33.00) 7.00 (1.00-25.00) 0.361 7.00 (0.00-33.00) 9.00 (2.00-19.00) 0.488 0.544 0.727
1: Mann-Whitney test;
2: Chronological age represented in years (yr.) and months (mo.);
3: SDS = standard deviation score;
4: BMI = body mass index;
5: GH Peak = maximum clonidine-stimulated GH concentration;
6: DGH = GH peak – baseline GH;
7: Values expressed as the median (minimum and maximum = minimum - maximum).
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the tests still provide important data for differential diagnosis
relative to other conditions that can present a clinical context
similar to that of isolated or idiopathic GHD (2,3).
In certain states in Brazil, including the state of Minas
Gerais, rhGH is provided only to children with GHD or TS.
Furthermore, in children with GHD, rhGH is only provided
when there is a lack of a GH response to two provocative tests,
even when there is a relevant clinical context (4,5).
As soon as the immunoradiometric, immunofluorometric
(IFMA) and ICMA methods were developed, experience
working with them demonstrated that a cut-off value of
10 ng/mL for the GH response to provocative tests was too
high for both the clonidine test and the ITT, leading to several
false-positive diagnoses (12-15). In a pilot study (22) involving
78 patients, a cut-off value more appropriate for the ICMA
methodwas adopted by our service (5 ng/mL), thus providing
a foundation for the current study.
Certain authors have suggested steroid priming for GH
stimulation tests, using initial administration of testosterone or
estradiol to achieve the traditional response of 10 ng/mL, as
with an RIA (27). We consider this artifice unnecessary because
the real goal is to differentiate children with GHD from normal
children or children with ISS, and to achieve this goal, a very
high cut-off level that has been arbitrarily defined in a less
sensitive and less specific method is not necessary (12-15).
In the current study, side effects of the clonidine
administered during the GH stimulation tests were observed
in 23% of the patients, as reported in the literature (28).
However, only somnolence and mild hypotension, with no
need for oral hydration or saline infusion, were observed, as
suggested by several authors (28,29). Batista et al. (30)
showed that a low dose of clonidine (0.1 mg/m2) is effective
as a GH-stimulating agent, resulting in lesser side effects.
Since then, we have standardized this clonidine dose, and
our data agree with those authors’ findings. Klein et al. (31)
studied the pharmacokinetics and pharmacodynamics of the
most employed clonidine dose, namely, 0.15/m2, when
administered to 40 children. The researchers found a higher
serum concentration than necessary to trigger GH release
according to model-based predictions, and they proposed
that a lower dose would be sufficient as a clonidine challenge
and could result in milder side effects.
In the current study, children were categorized based on
their height SDS to create a clinical spectrum that included
normal children and those with ISS (G2). We did not find any
differences in gender, developmental stage (pubertal or
prepubertal) or the GH response to clonidine between G1
and G2. Furthermore, the children were followed in the long
term during use of simple measures, such as a healthier diet
and exercise, and they spontaneously recovered their growth
paths based on their family characteristics and according to
normal curves, which clinically validated their laboratory data.
It is currently known that spontaneous GH secretion
increases during puberty, in parallel with increasing concentra-
tions of sexual steroids (32). However, most reports on
GH-provoking tests were performed in the prepubertal period
(6,9,10,12,13,27,30). In contrast, studies comparing GH peak
concentrations in response to secretagogues between the
prepubertal and the pubertal periods are rare (26), so this
aspect is still controversial. In the present study, we did not find
any difference in respect to this issue, similar to the findings of
Cavallo et al. (32) and Ghigo et al. (11). These authors observed
a GH response to several release-inducing agents, including
oral clonidine, and similarly to the present report, their pubertal
patients were in Tanner stages 2 and 3. Whether the inclusion of
patients in more advanced stages of puberty, with certainly
higher steroid concentrations, could have changed our results is
a question that remains to be answered.
Comparing the other two groups with the GHD group,
GH peak concentrations and DGH were significantly lower
in the GHD group. In addition, the ROC curve revealed that
a cut-off value of 3.0 ng/mL was able to differentiate patients
with GHD from those in the other groups.
The cut-off value of 3.0 ng/mL found in the present study
was similar to that in a previous study in which the authors
used immunometric methods (12); this is the minimal
GH response that a patient must reach to be considered
responsive to the clonidine test without the need for priming.
Using this cut-off value to analyze the patients from G1 and
G2, only 6 (3.02%) patients would need the second test (ITT),
whereas the cut-off value of 5 ng/mL resulted in 27 (13.56%)
patients needing to undergo the ITT.
Demonstrating and promoting a criterion for a positive
response to the clonidine test with a lower cut-off value in the
context of short stature, the Brazilian Unified Health System
(SUS) would have justification to not provide rhGH for these
children. However, as stated previously, the protocols need to
be adapted and to accept all GH indications supported by the
medical literature, which goes well beyond providing GH only
for patients with GHD or TS. The other causes of short stature
may require rhGH temporarily, which will help the individual
to achieve a stature that is compatible with good quality of life
and equal opportunities.
Certain authors have suggested that obesity can influence
the GH response to clonidine stimulation (34). In the current
study, individualizing the weight and BMI of each child
according to age and gender by calculating the BMI SDS, there
was no difference between the groups, and no correlation with
Figure 1 - ROC curve showing a value of 3.0 ng/mL for stimulated
GH (GH peak) as the reference value (cut-off), which was able to
differentiate normal children (G1) and children with ISS (G2)
from children with GHD (G3).
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the GH peak was observed; therefore, our data do not support
this proposition.
As observed by Galluzzi et al. (35), 93.96% of stimulated GH
peaks occurred within 90 minutes in G1 and G2. Therefore, the
testing period could be standardized to 90 minutes, as adopted
in the European and American protocols, which would reduce
the discomfort and cost of the procedure (30).
Based on the data obtained in the current study, we
conclude that the clonidine-stimulated GH concentrations
X3.0 ng/mL that were assayed by ICMA, within an
appropriate clinical and laboratorial context, indicated
normal GH responsiveness to stimulation. This value is
independent of gender, BMI SDS and pubertal developmental
stage. Moreover, the clonidine test could be performed with 3
blood collections, at baseline, 60 minutes and 90 minutes, to
improve the patient’s comfort and reduce the costs.
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